New Review Article Published by the Vizeacoumar Lab in Trends Mol Med
"Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell"
"Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell"
"Ischemia and reperfusion induce differential expression of calpastatin and its homologue high molecular weight calmodulin-binding protein in murine cardiomyocytes"
The Canadian Breast Cancer Foundation – Prairies/NWT (CBCF-P/NWT) is establishing a Scientific Advisory Council (SAC) in support of the Region’s research and fellowship grant programs and Dr. Bonham was identified as an ideal candidate to participate in this initiative.
Drs. Anderson and Vizeacoumar’s research project was highlighted in the Oct 22, 2014 issue of On Campus News in a article titled: “Cancer Care”.
Dr. Deborah Anderson (coPI: Dr. Franco Vizeacoumar) were awarded a new one-year operating grant from the Canadian Institutes of Health Research to support the project: “Targeting Metastatic Breast Cancer”.
"Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44+CD62Lhigh IL-7R+ CTLs with up- and downregulation of anti- and pro-apoptosis genes"
Dr. Erique Lukong (coPI: Dr. Keith Bonham) were awarded a new three-year operating grant from the Canadian Breast Cancer Foundation - Prairies/NWT Region. The title of their project is: "Epigenetic regulation of the FRK tumor suppressor gene in triple negative breast cancers".
The Cancer Research Society awarded Dr. Franco Vizeacoumar a two-year operating grant to work on a project titled: "Targeting Telomerase by Synthetic Lethality".
"Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment"
Jennifer Nyarko (Anderson lab) passed her PhD defence. Her thesis is titled: "Regulation of PDGF Receptor Trafficking and Signalling by the RabGAP Function of p85α". Jennifer is now training as a Post-Doctoral Fellow in the lab of Dr. Darrell Mousseau (Neurosciences Cluster, HSc, U of S).
Jeremy Marshall (Anderson and Moore Labs) and James Paul (Vizeacoumar and Freywald Labs) were both awarded two-year PRISM (Proteomics Research in Interactions and Structure of Macromolecules) graduate student scholarships.
"An improved method and cost effective strategy for soluble expression and purification of human N-myristoyltransferase 1 in E. coli"
The Saskatchewan Cancer Research Conference was held June 18 in Saskatoon and was well attended with close to 100 registered participants from a range of disciplines.
Gavin Cranmore-Sargison and co-applicants Deborah Anderson, Vijayananda Kundapur, Vitali Moiseenko were awarded a new operating grant from the Sylvia Fedoruk Canadian Centre for Nuclear Innovation (Fedoruk Centre). This project will be: “Investigating the radiobiological cell response to high energy mini-beam irradiations”.
"Insight into the roles of helicase motif Ia by characterizing Fanconi anemia group J protein (FANCJ) patient mutations"
Three new Saskatchewan Cancer Agency Research Grants were awarded.
A five year NSERC Discovery Grant was awarded to new investigator Dr. Franco Vizeacoumar. This grant supports a project called: "Functional Dissection of Epigenetic Silencing Machinery"
"Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation"
Levi Furber (Anderson lab) passed his PhD defence. His thesis is titled: "Regulation of constitutive platelet-derived growth factor receptor degradation by the 105 kilodalton isoform of ankyrin3". Beginning in the fall of 2014, Levi is in medical school at the University of Saskatchewan.
"BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration"
"Altered expression of calcineurin, calpain, calpastatin and HMWCaMBP in cardiac cells following ischemia and reperfusion"
Yetunde Ogunbolude (Bonham and Lukong labs) is the recipient of the first Lisa Rendall Breast Cancer Graduate Student Scholarship, a two-year award.
"HIV-1 Gag-specific exosome-targted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice."